Aliases:This biomarker is also known as:
- small-inducible cytokine A2,
- Monocyte chemoattractant protein 1,
- Monocyte chemotactic protein 1,
- Monocyte chemotactic and activating factor,
- monocyte chemoattractant protein-1,
- C-C motif chemokine 2,
- monocyte chemotactic protein 1,
- monocyte secretory protein JE,
- monocyte chemotactic and activating factor,
- Monocyte secretory protein JE,
- monocyte chemoattractant protein 1,
- chemokine (C-C motif) ligand 2,
- small inducible cytokine A2 (monocyte chemotactic protein 1, homologous to mouse Sig-je),
- Small-inducible cytokine A2,
- small inducible cytokine subfamily A (Cys-Cys), member 2,
From NCBI Gene: This gene is one of several cytokine genes clustered on the q-arm of chromosome 17. Chemokines are a superfamily of secreted proteins involved in immunoregulatory and inflammatory processes. The superfamily is divided into four subfamilies based on the arrangement of N-terminal cysteine residues of the mature peptide. This chemokine is a member of the CC subfamily which is characterized by two adjacent cysteine residues. This cytokine displays chemotactic activity for monocytes and basophils but not for neutrophils or eosinophils. It has been implicated in the pathogenesis of diseases characterized by monocytic infiltrates, like psoriasis, rheumatoid arthritis and atherosclerosis. It binds to chemokine receptors CCR2 and CCR4. [provided by RefSeq, Jul 2013]
There are no datasets associated with this biomarker.
The following organs have data associated with this biomarker…
|QA State:||Under Review|
No additional breast data available.
CCL2, also known as MCP-1, was one of numerous potential early detection biomarkers specific to triple-negative breast cancer in multiple pathways identified.
- Discovery and preliminary confirmation of novel early detection biomarkers for triple-negative breast cancer using preclinical plasma samples from the Women's Health Initiative observational study.
- Plasma biomarker profiles differ depending on breast cancer subtype but RANTES is consistently increased.
- HGNC entry for CCL2 from Genenames
- KEGG entry for CCL2 from Genome.jp
- Entrez entry for CCL2 all NCBI Databasese
- Human GEO Profiles for CCL2 from NCBI GEO Profiles
- Human Geo Datasets containing term CCL2 from NCBI GEO Datasets
- GWAS Study Datasets containing gene CCL2 from GWAS
- Human Single Nucleotide Polymorphisms info for CCL2
- Human Gene(s) with 'CCL2' as Gene Name/Alias
- Human Gene RefSeq for CCL2 from NCBI
- GeneCards entry for human CCL2
- UniProtKB/Swiss-Prot entry for CCL2 from Uniprot
- Human Protein RefSeq for CCL2 from NCBI
- FDA web page describing approval of CCL2
|UniProt Accession #:||P13500|
|Mutated Sites Count:||24|
|Associated Pubmed ID Count||4|
|Affected Protein Function Sites Count:||4|